• # LGM Pharma is a Atropine CAS# 51-55-8 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Atropine
  • CAS #: 51-55-8
  • Mode of Action:

    Atropine binds to and inhibit muscarinic acetylcholine receptors, producing a wide range of anticholinergic effects.

  • Pharmacodynamics:

    Atropine, a naturally occurring belladonna alkaloid, is a racemic mixture of equal parts of d- and l-hyoscyamine, whose activity is due almost entirely to the levo isomer of the drug. Atropine is commonly classified as an anticholinergic or antiparasympathetic (parasympatholytic) drug. More precisely, however, it is termed an antimuscarinic agent since it antagonizes the muscarine-like actions of acetylcholine and other choline esters. Adequate doses of atropine abolish various types of reflex vagal cardiac slowing or asystole. The drug also prevents or abolishes bradycardia or asystole produced by injection of choline esters, anticholinesterase agents or other parasympathomimetic drugs, and cardiac arrest produced by stimulation of the vagus. Atropine may also lessen the degree of partial heart block when vagal activity is an etiologic factor. Atropine in clinical doses counteracts the peripheral dilatation and abrupt decrease in blood pressure produced by choline esters. However, when given by itself, atropine does not exert a striking or uniform effect on blood vessels or blood pressure.

  • Metabolism:

    Much of the drug is destroyed by enzymatic hydrolysis, particularly in the liver. From 13 to 50% is excreted unchanged in the urine.

  • Toxicity:

    Oral, mouse: LD50 = 75 mg/kg. Symptoms of overdose includes widespread paralysis of parasympathetically innervated organs. Dry mucous membranes, widely dilated and nonresponsive pupils, tachycardia, fever and cutaneous flush are especially prominent, as are mental and neurological symptoms. In instances of severe intoxication, respiratory depression, coma, circulatory collapse and death may occur.

  • IUPAC: (1R, 3R, 5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 3-hydroxy-2-phenylpropanoate
  • ATC: A03BA01" S01FA01
  • DrugBank: DB00572
  • Formula: C17-H23-N-O3
  • Molecular Mass: 289.3727
  • Synonyms: (+,-)-Tropyl tropate, 1alphaH,5alphaH-Tropan-3alpha-ol (+-)-tropate (ester), 2-Phenylhydracrylic acid 3-alpha-tropanyl ester, AI3-60219, alpha-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, Atropen, Atropin, Atropin [German], Atropin-flexiolen, Atropina, Atropina [Italian], Atropine, Atropinol, Benzeneacetic acid, alpha-(hydroxymethyl)-8-methyl-8-azabicyclo(3,2,1)oct-3-yl ester, endo-(+-)-, Benzeneacetic acid, alpha-(hydroxymethyl)-8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, endo-(+-)-, beta-Phenyl-gamma-oxypropionsaeure-tropyl-ester, beta-Phenyl-gamma-oxypropionsaeure-tropyl-ester [German], beta-Phenyl-gamma-oxypropionsaure-tropyl-ester, beta-Phenyl-gamma-oxypropionsaure-tropyl-ester [German], CCRIS 3080, dl-Hyoscyamine, DL-Tropanyl 2-hydroxy-1-phenylpropionate, dl-Tropyltropate, EINECS 200-104-8, Eyesules, HSDB 2199, Isopto-atropine, Tropic acid, 3-alpha-tropanyl ester, Tropic acid, ester with tropine, Tropine tropate, Tropine, tropate (ester), Troyl tropate, UNII-7C0697DR9I
  • SMILES: CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(=O)C(CO)c3ccccc3
  • AHFS Code: 12:08.08, 52:24.00, 92:02.00*
  • InChl: 1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15+,16?
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants


  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service